Phase 2 Clinical Trial of GH001 in Bipolar II Disorder
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, open-label, single-arm Phase 2 clinical trial. Approximately 15
participants with clinically diagnosed bipolar disorder (BD) type II and experiencing a
current episode of depression will be included in this study. The participants will receive
an individualized dosing regimen (IDR) with at least one and up to three doses of GH001
administered within a single day.